Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Emergent Health Corp (EMGE)
King of Prussia, PA, US
Emergent Health Corp. focuses on the creation and distribution of advanced regenerative medicine, alongside a variety of nutraceuticals and plant-derived nutritional supplements. The company's product portfolio features Vita-Stim, a potent nutrient formulated to strengthen the immune system, promote stem cell vitality, and support general well-being. Another key offering is Neuvitale, which not only assists in nourishing stem cells but also serves as a methyl donor to safeguard DNA integrity. For appetite regulation, they provide Hungarest, a dietary aid designed to manage hunger signals originating from both the brain and stomach. Additionally, EmergentO2 is available as a water oxygenator, aiming to elevate oxygen levels within the bloodstream. The firm also develops and markets several solutions for diminishing facial wrinkles. These products are distributed through a wide network of health food stores, pharmacies, and diverse other retail channels, reaching consumers throughout the United States and globally. Based in King of Prussia, Pennsylvania, Emergent Health Corp. transitioned to private ownership as of August 26, 2014.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -66.67% | -50.00% | +0.00% | -50.00% | -96.67% | -99.82% | -99.71% | -99.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+184.5% ★ Q3'24: -100.0% (vs Q3'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+50.6% ★ Q3'24: +89.5% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-94.2%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-86.1%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q3'24: +2.2% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+54.5% Q3'24: +9.3% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.79× Q3'24: -239.36× (vs Q3'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gregory McCauley | Corporate Counsel | — | male |
| James W. Zimbler | Chief Executive Officer | — | male |
| Marvin Segel | Director & CMO | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EMGE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
